Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti–Tumor Necrosis Factor

Arthritis Care and Research

Volumn 69, Issue 6, 2017, Pages 783-793

  Hamann, Philip ^a   Holland, Richard ^b   Hyrich, Kimme ^c   Pauling, John D ^a   Shaddick, Gavin ^a   Nightingale, Alison ^a   McHugh, Neil ^a  

^a UNIVERSITY OF BATH   (United Kingdom)

^b ROYAL UNITED HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

AGE; ARTICLE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; FUNCTIONAL DISEASE; HUMAN; JOINT; META ANALYSIS; MULTICENTER STUDY (TOPIC); PREDICTOR VARIABLE; REMISSION; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SYSTEMATIC REVIEW; TENDER JOINT COUNT; TREATMENT FAILURE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; PROCEDURES; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85019015987     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23016     Document Type: Article

References (35)

1. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263–9.
2. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381–90.
3. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509.
4. Boers M, Kirwan JR, Tugwell P. The OMERACT Handbook. 2015. URL: https://www.omeract.org/omeract_publications.php.
5. Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res (Hoboken) 2010;62:1128–43.
6. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred Reporting Items for Systematic Review and Meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
7. Moher D, Liberati A, Tetzlaff J, Altman DG, and the PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
9. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
10. Van der Heijde DM, van 't Hof MA, Van Riel PL, Theunisse LA, Lubberts EW, Van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916–20.
11. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, Van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
12. Fransen J, Welsing P, De Keijzer R, Van Riel PC. Disease activity scores using C-reactive protein: CRP may replace ESR in the assessment of RA disease activity. 2003. URL: http://www.abstracts2view.com/eular/view.php?nu=EULAR03L1_2003THU0138.
13. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796–806.
14. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244–57.
15. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573–86.
16. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308–15.
17. Barnabe C, Homik J, Barr SG, Martin L, Maksymowych WP. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy. J Rheumatol 2014;41:1607–13.
18. Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015;74:389–95.
19. Balogh E, Madruga Dias J, Orr C, Mullan R, Harty L, FitzGerald O, et al. Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder. Arthritis Res Ther 2013;15:R221.
20. Einarsson JT, Geborek P, Saxne T, Kapetanovic MC. Sustained remission in tumor necrosis factor inhibitor-treated patients with rheumatoid arthritis: a population-based cohort study. J Rheumatol 2015;42:741–8.
21. Wells G, Shea B, O'Connell D, Peterson J, Welch V. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2008. URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
22. Collaboration C. Review Manager (RevMan): release 5.2.3. Copenhagen: The Nordic Cochrane Centre; 2012.
23. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1.0. The Cochrane Collaboration, 2011. URL: http://handbook.cochrane.org.
24. Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, et al. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken) 2011;63:856–64.
25. Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux CH, et al. Effect of discontinuing TNF-alpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76:350–5.
26. Navarro-Millan I, Chen L, Greenberg JD, Pappas DA, Curtis JR. Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients. Semin Arthritis Rheum 2013;43:137–43.
27. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;54:600–6.
28. Wetteland P, Røger M, Solberg HE, Iversen OH. Population-based erythrocyte sedimentation rates in 3910 subjectively healthy Norwegian adults: a statistical study based on men and women from the Oslo area. J Intern Med 1996;240:125–31.
29. National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor. 2010. URL: https://www.nice.org.uk/guidance/ta195/resources/adalimumab-etanercept-infliximab-rituximab-and-abatacept-for-the-treatment-of-rheumatoid-arthritis-after-the-failure-of-a-tnf-inhibitor-82598558287813.
30. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71:1524–9.
31. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:480–9.
32. World Health Organization. Towards a common language for functioning, disability and health: ICF. 2002. URL: http://www.who.int/classifications/icf/icfbeginnersguide.pdf.
33. Almeida C, Choy EH, Hewlett S, Kirwan JR, Cramp F, Chalder T, et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev 2016;6:CD008334.
34. Druce KL, Bhattacharya Y, Jones GT, Macfarlane GJ, Basu N. Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford) 2016;55:1786–90.
35. Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, et al. TNFα antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007;74:148–54.